
    
      Phase 1 dose escalation study to evaluate the safety, tolerability, and efficacy of a plasmid
      DNA encoding a variant of human IL-10. This 6-month study will follow subjects with severe
      osteoarthritis of the knee. Safety labs, physical exams, and blood levels of the IL-10
      variant will be assessed for tolerability and any adverse events associated with the
      treatment.
    
  